Avant Diagnostics (OTCMKTS:AVDX) and Fly Leasing (NYSE:FLY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Valuation & Earnings
This table compares Avant Diagnostics and Fly Leasing’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Avant Diagnostics||$110,000.00||61.27||-$11.75 million||N/A||N/A|
|Fly Leasing||$353.25 million||0.99||$2.59 million||$0.09||136.00|
Insider and Institutional Ownership
0.0% of Avant Diagnostics shares are held by institutional investors. Comparatively, 50.3% of Fly Leasing shares are held by institutional investors. 38.0% of Avant Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Avant Diagnostics has a beta of 3.73, indicating that its stock price is 273% more volatile than the S&P 500. Comparatively, Fly Leasing has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Avant Diagnostics and Fly Leasing, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fly Leasing has a consensus target price of $19.83, indicating a potential upside of 62.04%. Given Fly Leasing’s higher possible upside, analysts clearly believe Fly Leasing is more favorable than Avant Diagnostics.
This table compares Avant Diagnostics and Fly Leasing’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Fly Leasing beats Avant Diagnostics on 8 of the 11 factors compared between the two stocks.
Avant Diagnostics Company Profile
Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer; and MSPrecise, a DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. The company is based in Washington, District of Columbia.
Fly Leasing Company Profile
Fly Leasing Limited, through its subsidiaries, purchases and leases commercial aircrafts under multi-year contracts to various airlines worldwide. As of December 31, 2017, the company had a portfolio of 85 aircrafts, including 73 narrow-body passenger aircrafts and 12 wide-body passenger aircrafts. Fly Leasing Limited was founded in 2007 and is headquartered in Dún Laoghaire, Ireland.
Receive News & Ratings for Avant Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avant Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.